We have previously found that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and SLC22A18 represented a candidate biomarker for long-term survival in this disease, suggesting that SLC22A18 is an important tumor suppressor in glioma [10,11]. The gene discussed is SLC67A1; the disease is central nervous system cancer.